vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin
vTv Therapeutics (Nasdaq: VTVT) has received a Notice of Allowance from the USPTO for a patent application covering crystalline forms of salts and co-crystals of cadisegliatin, their lead drug candidate. The patent, which extends through 2041, strengthens the intellectual property protection for cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes (T1D) treatment.
The patent allowance represents a significant milestone in protecting vTv's innovative lead asset, reinforcing their commitment to developing novel therapeutic solutions.
vTv Therapeutics (Nasdaq: VTVT) ha ricevuto una notifica di concessione dall'USPTO per una domanda di brevetto relativa alle forme cristalline di sali e co-cristalli di cadisegliatin, il loro principale candidato farmaco. Il brevetto, valido fino al 2041, rafforza la protezione della proprietà intellettuale di cadisegliatin, una potenziale terapia orale adiuvante all'insulina per il trattamento del diabete di tipo 1 (T1D).
L'ammissione del brevetto rappresenta un traguardo significativo nella tutela dell'asset innovativo di vTv, confermando il loro impegno nello sviluppo di nuove soluzioni terapeutiche.
vTv Therapeutics (Nasdaq: VTVT) ha recibido una notificación de concesión de la USPTO para una solicitud de patente que cubre las formas cristalinas de sales y co-cristales de cadisegliatin, su principal candidato farmacológico. La patente, que se extiende hasta 2041, refuerza la protección de la propiedad intelectual de cadisegliatin, una posible terapia oral adyuvante a la insulina para el tratamiento de la diabetes tipo 1 (T1D).
La concesión de la patente constituye un hito importante en la protección del activo innovador de vTv y reafirma su compromiso con el desarrollo de nuevas soluciones terapéuticas.
vTv Therapeutics (Nasdaq: VTVT)가 USPTO로부터 cadisegliatin의 염 및 코크리스탈의 결정형을 다루는 특허 출원에 대한 등록 허가 통지서를 받았습니다. 이 특허는 2041년까지 유효하며, 인슐린의 경구 보조요법으로서 제1형 당뇨병 (T1D) 치료에 사용할 수 있는 잠재적 최초 계열 약물인 cadisegliatin의 지식재산권을 강화합니다.
이번 특허 허가는 vTv의 혁신적 주력 자산 보호에 있어 중요한 이정표로, 새로운 치료 솔루션 개발에 대한 회사의 의지를 더욱 공고히 합니다.
vTv Therapeutics (Nasdaq: VTVT) a reçu un avis d'acceptation de l'USPTO pour une demande de brevet couvrant les formes cristallines de sels et co-cristaux de cadisegliatin, leur candidat-médicament principal. Le brevet, qui court jusqu'en 2041, renforce la protection de la propriété intellectuelle de cadisegliatin, une thérapie orale adjuvante potentielle à l'insuline pour le traitement du diabète de type 1 (T1D).
Cette acceptation constitue un jalon important pour la protection de l'atout innovant de vTv et confirme son engagement dans le développement de nouvelles solutions thérapeutiques.
vTv Therapeutics (Nasdaq: VTVT) hat vom USPTO eine Zulassungsmitteilung (Notice of Allowance) für eine Patentanmeldung erhalten, die kristalline Formen von Salzen und Co-Kristallen von cadisegliatin abdeckt, ihrem führenden Wirkstoffkandidaten. Das Patent, das bis 2041 läuft, stärkt den Schutz des geistigen Eigentums für cadisegliatin, eine potenzielle orale Zusatztherapie zur Insulinbehandlung bei Typ‑1‑Diabetes (T1D).
Die Zulassung der Patentanmeldung stellt einen wichtigen Meilenstein beim Schutz des innovativen Leitprodukts von vTv dar und unterstreicht das Engagement des Unternehmens, neue therapeutische Lösungen zu entwickeln.
- Patent protection for cadisegliatin extended through 2041
- Strengthened intellectual property position for lead drug candidate
- Development of potential first-in-class oral therapy for type 1 diabetes
- None.
HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application directed to compositions of matter of crystalline forms of salts and co-crystals of cadisegliatin. The patent term runs through 2041.
“We are pleased with the outcome of the prosecution of this patent as it further strengthens the protection around cadisegliatin,” said Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics. “This successful patent application demonstrates our strong commitment to protecting the innovation of our lead asset and is another important milestone for vTv Therapeutics.”
About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated as a potential first-in-class oral adjunctive treatment for Type 1 diabetes (T1D). In non-clinical studies, cadisegliatin, acting selectively on the liver, increased the activity of glucokinase independently from insulin which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) and is currently being studied in the Phase 3 CATT1 trial.
Cadisegliatin is under investigation and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com
FAQ
What patent did vTv Therapeutics (VTVT) receive for cadisegliatin?
What is cadisegliatin being developed for by vTv Therapeutics?
How long will vTv Therapeutics' new patent protection for cadisegliatin last?
What type of drug is VTVT's cadisegliatin?
